Bold claim: GLP-1R agonists may boost recovery for stroke patients with large vessel occlusion during reperfusion therapy. A recent phase 2 randomized trial suggests these diabetes drugs could offer neuroprotective benefits beyond their usual use. Published in Nature Communications in 2025, the study examined GLP-1R agonists as an adjunct treatment to standard reperfusion care for LVO strokes, aiming to improve neurological outcomes and overall safety.
In the trial, participants with LVO stroke were divided into two groups: one received standard reperfusion therapy, while the other received the same therapy plus a GLP-1R agonist. The researchers tracked key outcomes such as neurological function and safety signals. Results showed that those treated with GLP-1R agonists demonstrated measurable improvements compared with the control group, hinting at potential neuroprotective effects during and after reperfusion.
Despite these promising signals, the researchers underscore that confirming efficacy and safety across a broader population will require larger-scale studies. The findings open an intriguing avenue for repurposing GLP-1R agonists in acute stroke care, but they also invite further debate about practical implementation, optimal dosing, timing, and patient selection.
If you’re following the evolving landscape of stroke therapeutics, this study adds a provocative piece to the puzzle: could commonly used antidiabetic meds become part of standard neuroprotection strategies? What are the trade-offs, and where should the next trials focus to settle lingering questions? Share your thoughts below.
Source: Nature Communications, 2025
Date: December 14, 2025
© GeneOnline News
